

DAFTAR PUSTAKA

- ACS. (2019). Lung Cancer Causes, Risk Factors, and Prevention. *The American Cancer Society*, 1–14.
- AKIHIRO MURAKAMI, T. N. M. K. S. N. O. T. H. K. and N. S. (2006). Suppression of SCC antigen promotes cancer cell invasion and migration through the decrease in E-cadherin expression. *INTERNATIONAL JOURNAL OF ONCOLOGY* , 29, 1231–1235.
- Alfarisa, S., Mitra, E., & Wahyuni, S. (2023). Karakteristik Pasien Kanker Paru di RSUP Dr. M. Djamil Padang Tahun 2021. *Scientific Journal*, 2(6), 141–149. <https://doi.org/10.56260/sciena.v2i6.116>
- American Cancer Society. (2019). Cancer Facts and Figures 2019. *American Cancer Society*, 1–76.
- An, S., Shim, H., Kim, K., Kim, B., Bang, H. J., Do, H., Lee, H. R., & Kim, Y. (2022). Pretreatment inflammatory markers predicting treatment outcomes in colorectal cancer. *Annals of Coloproctology*, 38(2), 97–108. <https://doi.org/10.3393/ac.2021.01004.0143>
- Antoch, G., Stattaus, J., Nemat, A. T., Marnitz, S., Beyer, T., Kuehl, H., Bockisch, A., Debatin, J. F., & Freudenberger, L. S. (2003). Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. *Radiology*, 229(2), 526–533. <https://doi.org/10.1148/radiol.2292021598>
- Bar-Ad, V., Palmer, J., Li, L., Lai, Y., Lu, B., Myers, R. E., Ye, Z., Axelrod, R., Johnson, J. M., & Werner-Wasik, M. (2017). Neutrophil to lymphocyte ratio associated with prognosis of lung cancer. *Clinical and Translational Oncology*, 19, 711–717.
- Biswas, T., Gawdi, R., Jindal, C., Iyer, S., Kang, K. H., Bajor, D., Machtay, M., Choi, Y. M., & Efird, J. T. (2021). Pretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: Confirmatory results from the PROCLAIM phase III clinical trial. *Journal of Thoracic Disease*, 13(10), 5617–5626. <https://doi.org/10.21037/jtd-21-1018>
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence

- and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 68(6), 394–424. <https://doi.org/10.3322/caac.21492>
- Budisan, L., Zanoaga, O., Braicu, C., Pirlog, R., Covaliu, B., Esanu, V., Korban, S. S., & Berindan-Neagoe, I. (2021). Links between Infections, Lung Cancer, and the Immune System. *International Journal of Molecular Sciences*, 22(17). <https://doi.org/10.3390/ijms22179394>
- Campian, J. L., Ye, X., Brock, M., & Grossman, S. A. (2013). Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. *Cancer Investigation*, 31(3), 183–188. <https://doi.org/10.3109/07357907.2013.767342>
- Catanzaro, J. M., Sheshadri, N., Pan, J. A., Sun, Y., Shi, C., Li, J., Powers, R. S., Crawford, H. C., & Zong, W. X. (2014). Oncogenic Ras induces inflammatory cytokine production by upregulating the squamous cell carcinoma antigens SerpinB3/B4. *Nature Communications*, 5. <https://doi.org/10.1038/ncomms4729>
- Chen, Z. Q., Huang, L. S., & Zhu, B. (2018). Assessment of seven clinical tumor markers in diagnosis of non-small-cell lung cancer. *Disease Markers*, 2018. <https://doi.org/10.1155/2018/9845123>
- Cheng, H., Bhushan, S., Li, N., Xiao, Z., & Gao, K. (2022). Preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are correlated with tumor–node–metastasis stages in patients with non-small cell lung cancer. *Journal of Cancer Research and Therapeutics*, 18(6), 1666–1673. https://doi.org/10.4103/jcrt.jcrt_473_21
- Clark, S. B., & Alsubait, S. (2022). *Non Small Cell Lung Cancer*. StatPearls Publishing, Treasure Island (FL).
- de Groot, P. M., Wu, C. C., Carter, B. W., & Munden, R. F. (2018). The epidemiology of lung cancer. *Translational Lung Cancer Research; Vol 7, No 3 (June 14, 2018): Translational Lung Cancer Research (Lung Cancer Screening)*.
- De Leyn, P., Doms, C., Kuzdzal, J., Lardinois, D., Passlick, B., Rami-Porta, R., Turna, A., Van Schil, P., Venuta, F., Waller, D., Weder, W., & Zielinski, M. (2014). Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. *European Journal of Cardio-Thoracic Surgery: Official Journal of the European Association for*

- Cardio-Thoracic Surgery*, 45(5), 787–798.
<https://doi.org/10.1093/ejcts/ezu028>
- Dela Cruz, C. S. (2011). Lung Cancer: Epidemiology, Etiology, and Prevention. *Clinics in Chest Medicine*, 32(4), 605–644.
<https://doi.org/10.1016/j.ccm.2011.09.001>
- Detterbeck, F. C., Boffa, D. J., Kim, A. W., & Tanoue, L. T. (2017). The Eighth Edition Lung Cancer Stage Classification. *Chest*, 151(1), 193–203.
<https://doi.org/10.1016/j.chest.2016.10.010>
- Durgeau, A., Virk, Y., Corgnac, S., & Mami-Chouaib, F. (2018). Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy. *Frontiers in Immunology*, 9, 336391.
- Durham, A. L., & Adcock, I. M. (2015). The relationship between COPD and lung cancer. *Lung Cancer (Amsterdam, Netherlands)*, 90(2), 121–127.
<https://doi.org/10.1016/j.lungcan.2015.08.017>
- Feinstein, M. B., & Bach, P. B. (2000). Epidemiology of lung cancer. *Chest Surgery Clinics of North America*, 10(4), 653–661.
- Forgacs, E., Zöchbauer-Müller, S., Oláh, E., & Minna, J. D. (2001). Molecular genetic abnormalities in the pathogenesis of human lung cancer. *Pathology and Oncology Research*, 7(1), 6–13.
<https://doi.org/10.1007/BF03032598>
- Fu, J., Wang, W., Wang, Y., Liu, C., & Wang, P. (2019). The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer. In *Radiation Oncology* (Vol. 14, Issue 1). BioMed Central Ltd.
<https://doi.org/10.1186/s13014-019-1355-4>
- Gridelli, C., Rossi, A., Carbone, D. P., Guarize, J., Karachaliou, N., Mok, T., Petrella, F., Spaggiari, L., & Rosell, R. (2015). Non-small-cell lung cancer. *Nature Reviews Disease Primers*, 1, 1–16.
<https://doi.org/10.1038/nrdp.2015.9>
- Harrison, P. T., Vyse, S., & Huang, P. H. (2020). Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. *Seminars in Cancer Biology*, 61(August 2019), 167–179.
<https://doi.org/10.1016/j.semcancer.2019.09.015>

- Holdenrieder, S., Molina, R., Qiu, L., Zhi, X., Rutz, S., Engel, C., Kasper-Sauer, P., Dayyani, F., & Korse, C. M. (2018a). Technical and clinical performance of a new assay to detect squamous cell carcinoma antigen levels for the differential diagnosis of cervical, lung, and head and neck cancer. *Tumor Biology*, 40(4). <https://doi.org/10.1177/1010428318772202>
- Holdenrieder, S., Molina, R., Qiu, L., Zhi, X., Rutz, S., Engel, C., Kasper-Sauer, P., Dayyani, F., & Korse, C. M. (2018b). Technical and clinical performance of a new assay to detect squamous cell carcinoma antigen levels for the differential diagnosis of cervical, lung, and head and neck cancer. *Tumor Biology*, 40(4). <https://doi.org/10.1177/1010428318772202>
- Holdenrieder, S., Molina, R., Qiu, L., Zhi, X., Rutz, S., Engel, C., Kasper-Sauer, P., Dayyani, F., & Korse, C. M. (2018c). Technical and clinical performance of a new assay to detect squamous cell carcinoma antigen levels for the differential diagnosis of cervical, lung, and head and neck cancer. *Tumor Biology*, 40(4). <https://doi.org/10.1177/1010428318772202>
- Hubers, A. J., Prinsen, C. F. M., Sozzi, G., Witte, B. I., & Thunnissen, E. (2013). Molecular sputum analysis for the diagnosis of lung cancer. *British Journal of Cancer*, 109(3), 530–537. <https://doi.org/10.1038/bjc.2013.393>
- Joseph, J., & Rotty, L. W. A. (2020). Kanker Paru: Laporan Kasus. *Medical Scope Journal*, 2(1), 17–25. <https://doi.org/10.35790/msj.v2i1.31108>
- Jumeau, R., Vilotte, F., Durham, A. D., & Ozsahin, E. M. (2019). Current landscape of palliative radiotherapy for non-small-cell lung cancer. *Translational Lung Cancer Research*, 8(7), S192–S201. <https://doi.org/10.21037/tlcr.2019.08.10>
- Jusuf, A. (2017). Dasar Diagnosis Kanker Paru. In A. Jusuf (Ed.), *Universitas Indonesia* (1st ed.). UI-Press.
- Kacan, T., Babacan, N. A., Seker, M., Yucel, B., Bahceci, A., Eren, A. A., Eren, M. F., & Kilickap, S. (2014). Could the neutrophil to lymphocyte ratio be a poor prognostic factor for non small cell lung cancers? *Asian Pacific Journal of Cancer Prevention: APJCP*, 15(5), 2089–2094. <https://doi.org/10.7314/apjcp.2014.15.5.2089>

- Kagohashi, K., Satoh, H., Kurishima, K., Kadono, K., Ishikawa, H., Ohtsuka, M., & Sekizawa, K. (2008a). Squamous cell carcinoma antigen in lung cancer and nonmalignant respiratory diseases. *Lung*, 186(5), 323–326. <https://doi.org/10.1007/s00408-008-9108-4>
- Kagohashi, K., Satoh, H., Kurishima, K., Kadono, K., Ishikawa, H., Ohtsuka, M., & Sekizawa, K. (2008b). Squamous cell carcinoma antigen in lung cancer and nonmalignant respiratory diseases. *Lung*, 186(5), 323–326. <https://doi.org/10.1007/s00408-008-9108-4>
- Kanwal, M., Ding, X. J., & Cao, Y. (2017). Familial risk for lung cancer. *Oncology Letters*, 13(2), 535–542. <https://doi.org/10.3892/ol.2016.5518>
- Kemal, Y., Yucel, I., Ekiz, K., Demirag, G., Yilmaz, B., Teker, F., & Ozdemir, M. (2014). Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis. *Asian Pacific Journal of Cancer Prevention*, 15(6), 2651–2654. <https://doi.org/10.7314/APJCP.2014.15.6.2651>
- Kementerian Kesehatan RI. (2017). Pedoman Nasional Pelayanan Kedokteran Kanker Paru. *Jurnal Penelitian Pendidikan Guru Sekolah Dasar*, 6(August), 128.
- Kementerian Kesehatan RI. (2018). Pedoman Pengendalian Faktor Risiko Kanker Paru. In *Direktorat Jenderal Pencegahan dan Pengendalian Penyakit* (p. 29).
- Kos, F. T., Hocaazade, C., Kos, M., Uncu, D., Karakas, E., Dogan, M., Uncu, H. G., Ozdemir, N., & Zengin, N. (2015). Assessment of prognostic value of “neutrophil to lymphocyte ratio” and “prognostic nutritional index” as a sytemic inflammatory marker in non-small cell lung cancer. *Asian Pacific Journal of Cancer Prevention*, 16(9), 3997–4002. <https://doi.org/10.7314/APJCP.2015.16.9.3997>
- Kristina, S. A., Endarti, D., Aditama, H., & American Cancer Society. (2018). Global Cancer - Facts&Figures 4th Edition. *American Cancer Society*, 29(1), 138–144.
- Kufe, D. (2005). *Multistage Carcinogenesis*. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. *Holland-Frei Cancer Medicine*. 6th edition. Hamilton (ON): BC Decker; 2003. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK13982/>.

- Lackey, A., & Donington, J. (2013). Surgical management of lung cancer. *Seminars in Interventional Radiology*, 30(2), 133–140. <https://doi.org/10.1055/s-0033-1342954>
- Laporan Riskesdas 2018 Nasional*. (n.d.).
- Larosa, D. F., & Orange, J. S. (2008). Lymphocytes. *The Journal of Allergy and Clinical Immunology*, 121(2 Suppl), S364-9; quiz S412. <https://doi.org/10.1016/j.jaci.2007.06.016>
- Li, Q., Geng, S., Zhang, X., & Jia, Z. (2023). Significance of tumor markers combined with neutrophil to lymphocyte ratio, D-dimer and T-lymphocyte in the diagnosis of colon cancer. *Pakistan Journal of Medical Sciences*, 39(4), 1003–1007. <https://doi.org/10.12669/pjms.39.4.7157>
- Li, Y., Zhang, Z., Hu, Y., Yan, X., Song, Q., Wang, G., Chen, R., Jiao, S., & Wang, J. (2020). Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs). *Frontiers in Oncology*, 10(June), 1–13. <https://doi.org/10.3389/fonc.2020.00654>
- Lohinai, Z., Bonanno, L., Aksarin, A., Pavan, A., Megyesfalvi, Z., Santa, B., Hollosi, V., Hegedus, B., Moldvay, J., Conte, P. F., Ter-Ovanesov, M., Bilan, E., Dome, B., & Weiss, G. J. (2019). Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer. *PeerJ*, 2019(7). <https://doi.org/10.7717/peerj.7232>
- Masucci, M. T., Minopoli, M., & Carriero, M. V. (2019). Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy. *Frontiers in Oncology*, 9, 1146. <https://doi.org/10.3389/fonc.2019.01146>
- Mino, N., Iio, A., & Hamamoto, K. (1988). Availability of tumor-antigen 4 as a marker of squamous cell carcinoma of the lung and other organs. *Cancer*, 62(4), 730–734. [https://doi.org/10.1002/1097-0142\(19880815\)62:4<730::AID-CNCR2820620415>3.0.CO;2-W](https://doi.org/10.1002/1097-0142(19880815)62:4<730::AID-CNCR2820620415>3.0.CO;2-W)
- Murakami, A., Fukushima, C., Yositori, K., Sueoka, K., Nawata, S., Fujimoto, M., Nakamura, K., & Sugino, N. (2010). Tumor-related protein, the squamous cell carcinoma antigen binds to the intracellular protein

- carbonyl reductase. *International Journal of Oncology*, 36(6), 1395–1400.
https://doi.org/10.3892/ijo_00000624
- Myers, D. J., & Wallen, J. M. (2024). *Lung Adenocarcinoma*.
- Nakajima, T., & Yasufuku, K. (2011). How I do it--optimal methodology for multidirectional analysis of endobronchial ultrasound-guided transbronchial needle aspiration samples. *Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer*, 6(1), 203–206. <https://doi.org/10.1097/JTO.0b013e318200f496>
- NCCN®. (2020). *The National Comprehensive Cancer Network® Guidelines for Non-Small Cell Lung Cancer (NSCLC) - Version 8.2020*.
- Nguyen, M. L. T., Pham, C., Le, Q. V., Nham, P. L. T., Tran, D. H., Le, T. S., Hoang, V. T., Can, V. M., Nguyen, L. T., & Bui, K. C. (2023). The diagnostic and prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio on gastric cancer patients. *Medicine (United States)*, 102(31), E34357.
<https://doi.org/10.1097/MD.00000000000034357>
- Niho, S., & Shinkai, T. (2001). Tumor markers in lung cancer. *Gan to kagaku ryoho. Cancer & chemotherapy*, 28(13), 2089–2093.
- Palucka, A. K., & Coussens, L. M. (2016). The Basis of Oncoimmunology. *Cell*, 164(6), 1233–1247. <https://doi.org/10.1016/j.cell.2016.01.049>
- Passaro, A., Malapelle, U., Del Re, M., Attili, I., Russo, A., Guerini-Rocco, E., Fumagalli, C., Pisapia, P., Pepe, F., De Luca, C., Cucchiara, F., Troncone, G., Danesi, R., Spaggiari, L., De Marinis, F., & Rolfo, C. (2020). Understanding EGFR heterogeneity in lung cancer. *ESMO Open*, 5(5), e000919. <https://doi.org/10.1136/esmoopen-2020-000919>
- Rangachari, D., VanderLaan, P. A., Shea, M., Le, X., Huberman, M. S., Kobayashi, S. S., & Costa, D. B. (2017). Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma. *Journal of Thoracic Oncology*, 12(5), 878–883. <https://doi.org/10.1016/j.jtho.2016.12.026>
- Riudavets, M., Garcia de Herreros, M., Besse, B., & Mezquita, L. (2022). Radon and Lung Cancer: Current Trends and Future Perspectives. *Cancers*, 14(13), 1–17. <https://doi.org/10.3390/cancers14133142>

- Roberts, M., Ogden, J., Hossain, A. S. M., Chaturvedi, A., Kerr, A. R. W., Dive, C., Beane, J. E., & Lopez-Garcia, C. (2023). Interrogating the precancerous evolution of pathway dysfunction in lung squamous cell carcinoma using XTABLE. *ELife*, 12, e77507. <https://doi.org/10.7554/eLife.77507>
- Rosales, C. (2018). Neutrophil: A cell with many roles in inflammation or several cell types? In *Frontiers in Physiology* (Vol. 9, Issue FEB). Frontiers Media S.A. <https://doi.org/10.3389/fphys.2018.00113>
- Sanchez-De Cos, J., Masa, F., De la Cruz, J. L., Disdier, C., & Vergara, C. (1994a). Squamous cell carcinoma antigen (SCC Ag) in the diagnosis and prognosis of lung cancer. *Chest*, 105(3), 773–776. <https://doi.org/10.1378/chest.105.3.773>
- Sanchez-De Cos, J., Masa, F., De la Cruz, J. L., Disdier, C., & Vergara, C. (1994b). Squamous cell carcinoma antigen (SCC Ag) in the diagnosis and prognosis of lung cancer. *Chest*, 105(3), 773–776. <https://doi.org/10.1378/chest.105.3.773>
- Sarhadi, V. K., & Armengol, G. (2022). Molecular Biomarkers in Cancer. *Biomolecules*, 12(8), 1–39. <https://doi.org/10.3390/biom12081021>
- Schabath, M. B., & Cote, M. L. (2019). Cancer progress and priorities: Lung cancer. *Cancer Epidemiology Biomarkers and Prevention*, 28(10), 1563–1579. <https://doi.org/10.1158/1055-9965.EPI-19-0221>
- Sheshadri, N., Catanzaro, J. M., Bott, A. J., Sun, Y., Ullman, E., Chen, E. I., Pan, J. A., Wu, S., Crawford, H. C., Zhang, J., & Zong, W. X. (2014). SCCA1/SERPINB3 promotes oncogenesis and epithelial-mesenchymal transition via the unfolded protein response and IL6 signaling. *Cancer Research*, 74(21), 6318–6329. <https://doi.org/10.1158/0008-5472.CAN-14-0798>
- Silvestri, G. A., Tanoue, L. T., Margolis, M. L., Barker, J., & Detterbeck, F. (2003). The noninvasive staging of non-small cell lung cancer: the guidelines. *Chest*, 123(1 Suppl), 147S-156S. https://doi.org/10.1378/chest.123.1_suppl.147s
- Song, W. an, Liu, X., Tian, X. D., Wang, W., Liang, C. Y., Zhang, T., Guo, J. T., Peng, Y. H., & Zhou, N. K. (2011). Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific

- enolase in lung cancer diagnosis: A prospective study from China. *Chinese Medical Journal*, 124(20), 3244–3248. <https://doi.org/10.3760/cma.j.issn.0366-6999.2011.20.007>
- Spiro, S. G., & Gould, M. K. (2007). Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). *Chest*, 132(3 Suppl), 149S-160S. <https://doi.org/10.1378/chest.07-1358>
- Stading, R., Gastelum, G., Chu, C., Jiang, W., & Moorthy, B. (2021). Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): Implications for human lung cancer. *Seminars in Cancer Biology*, 76, 3–16. <https://doi.org/10.1016/j.semcancer.2021.07.001>
- Stefaniuk, P., Szymczyk, A., & Podhorecka, M. (2020). The neutrophil to lymphocyte and lymphocyte to monocyte ratios as new prognostic factors in hematological malignancies – a narrative review. In *Cancer Management and Research* (Vol. 12, pp. 2961–2977). Dove Medical Press Ltd. <https://doi.org/10.2147/CMAR.S245928>
- Stojkovic Lalosevic, M., Pavlovic Markovic, A., Stankovic, S., Stojkovic, M., Dimitrijevic, I., Radoman Vujacic, I., Lalic, D., Milovanovic, T., Domic, I., & Krivokapic, Z. (2019). Combined Diagnostic Efficacy of Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Mean Platelet Volume (MPV) as Biomarkers of Systemic Inflammation in the Diagnosis of Colorectal Cancer. *Disease Markers*, 2019, 6036979. <https://doi.org/10.1155/2019/6036979>
- Sun, Y., Sheshadri, N., & Zong, W. X. (2017). SERPINB3 and B4: From biochemistry to biology. In *Seminars in Cell and Developmental Biology* (Vol. 62, pp. 170–177). Academic Press. <https://doi.org/10.1016/j.semcdb.2016.09.005>
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021a). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>

- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021b). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>
- Tony, V., Sathyamurthy, A., Ramireddy, J. K., Iswarya, S. J., Gowri, S. M., Thomas, A., Peedicayil, A., & Ram, T. S. (2023). Role of squamous cell carcinoma antigen in prognostication, monitoring of treatment response, and surveillance of locally advanced cervical carcinoma. *Journal of Cancer Research and Therapeutics*, 19(5), 1236–1240. https://doi.org/10.4103/jcrt.jcrt_335_21
- Turato, C., & Pontisso, P. (2015). SERPINB3 (Serpine Peptidase Inhibitor, Clade B (Ovalbumin), Member 3). *Atlas of Genetics and Cytogenetics in Oncology and Haematology*, 3. <https://doi.org/10.4267/2042/56413>
- Uguen, M., Dewitte, J.-D., Marcorelles, P., Loddé, B., Pougnet, R., Saliou, P., De Braekeleer, M., & Uguen, A. (2017). Asbestos-related lung cancers: A retrospective clinical and pathological study. *Molecular and Clinical Oncology*, 7(1), 135–139. <https://doi.org/10.3892/mco.2017.1277>
- Unal, D., Eroglu, C., Kurtul, N., Oguz, A., & Tasdemir, A. (2013). Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? *Asian Pacific Journal of Cancer Prevention : APJCP*, 14(9), 5237–5242. <https://doi.org/10.7314/apjcp.2013.14.9.5237>
- Vassilakopoulos, T., Troupis, T., Sotiropoulou, C., Zacharatos, P., Katsaounou, P., Parthenis, D., Noussia, O., Troupis, G., Papiris, S., Kittas, C., Roussos, C., Zakynthinos, S., & Gorgoulis, V. (2001). Diagnostic and prognostic significance of squamous cell carcinoma antigen in non-small cell lung cancer. In *Lung Cancer* (Vol. 32). www.elsevier.nl/locate/lungcan
- Venuta, F., Diso, D., Onorati, I., Anile, M., Mantovani, S., & Rendina, E. A. (2016). Lung cancer in elderly patients. *Journal of Thoracic Disease*, 8(Suppl 11), S908–S914. <https://doi.org/10.21037/jtd.2016.05.20>
- Vidalino, L., Doria, A., Quarta, S., Zen, M., Gatta, A., & Pontisso, P. (2009). SERPINB3, apoptosis and autoimmunity. In *Autoimmunity Reviews* (Vol. 9, Issue 2, pp. 108–112). <https://doi.org/10.1016/j.autrev.2009.03.011>

- Wu, S. G., & Shih, J. Y. (2018). Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. *Molecular Cancer*, 17(1), 1–14. <https://doi.org/10.1186/s12943-018-0777-1>
- Xu, F., Xu, P., Cui, W., Gong, W., Wei, Y., Liu, B., & Dong, J. (2018a). Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios may aid in identifying patients with non-small cell lung cancer and predicting Tumor-Node-Metastasis stages. *Oncology Letters*, 16(1), 483–490. <https://doi.org/10.3892/ol.2018.8644>
- Xu, F., Xu, P., Cui, W., Gong, W., Wei, Y., Liu, B., & Dong, J. (2018b). Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios may aid in identifying patients with non-small cell lung cancer and predicting tumor-node-metastasis stages. *Oncology Letters*, 16(1), 483–490. <https://doi.org/10.3892/ol.2018.8644>
- Yang, D., Wang, J., & Zhang, L. (2019a). Serum SCCA levels in patients suffering cancers or other diseases. In *Progress in Molecular Biology and Translational Science* (Vol. 162, pp. 165–175). Elsevier B.V. <https://doi.org/10.1016/bs.pmbts.2018.12.004>
- Yang, D., Wang, J., & Zhang, L. (2019b). Serum SCCA levels in patients suffering cancers or other diseases. In *Progress in Molecular Biology and Translational Science* (Vol. 162, pp. 165–175). Elsevier B.V. <https://doi.org/10.1016/bs.pmbts.2018.12.004>
- Yu, Y., Qian, L., & Cui, J. (2017). Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients. *Molecular and Clinical Oncology*, 7(3), 498–506. <https://doi.org/10.3892/mco.2017.1342>
- Zappa, C., & Mousa, S. A. (2016). Non-small cell lung cancer: Current treatment and future advances. *Translational Lung Cancer Research*, 5(3), 288–300. <https://doi.org/10.21037/tlcr.2016.06.07>
- Zhang, Z., Li, Z., Zhang, X., Ye, W., Chen, J., Wang, L., Lin, Z., Li, J., & Li, Z. (2023). Association between secondhand smoke and cancers in adults in the US population. *Journal of Cancer Research and Clinical Oncology*, 149(7), 3447–3455. <https://doi.org/10.1007/s00432-022-04266-w>

- Zhou, J., Liu, H., Jiang, S., & Wang, W. (2023). Role of tumor-associated neutrophils in lung cancer (Review). *Oncology Letters*, 25(1). <https://doi.org/10.3892/ol.2022.13588>
- Zhu, H. (2022). Squamous Cell Carcinoma Antigen: Clinical Application and Research Status. In *Diagnostics* (Vol. 12, Issue 5). MDPI. <https://doi.org/10.3390/diagnostics12051065>

LAMPIRAN

Lampiran 1. Persetujuan Etik Penelitian

 KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN RSPTN UNIVERSITAS HASANUDDIN RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR Sekretariat : Lantai 2 Gedung Laboratorium Terpadu JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245. Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431			
REKOMENDASI PERSETUJUAN ETIK Nomor : 171/UN4.6.4.5.31/ PP36/ 2024			
Tanggal: 15 Maret 2024			
Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :			
No Protokol	UH24020137	No Sponsor	
Peneliti Utama	dr. Tuti Alawiyah	Sponsor	
Judul Peneliti	Uji Diagnostik Rasio Neutrofil Limfosit dan Kadar Squamous Cell Carcinoma Antigen (SCCA) Serum pada Pasien Kanker Paru		
No Versi Protokol	1	Tanggal Versi	29 Februari 2024
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku 15 Maret 2024 sampai 15 Maret 2025	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi, PhD, SpMK, Subsp. Bakt(K)	Tanda tangan 	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan 	
Kewajiban Peneliti Utama: • Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan • Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan • Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah • Menyerahkan laporan akhir setelah Penelitian berakhir • Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation) • Mematuhi semua peraturan yang ditentukan			

Lampiran 2. Naskah Penjelasan untuk Mendapat Persetujuan dari Subjek Penelitian

FORMULIR PERSETUJUAN SETELAH PENJELASAN (PSP) (INFORMED CONSENT)

Selamat pagi Bapak / Ibu / Saudara (i), saya **dr. Tuti Alawiyah**, bermaksud untuk melakukan penelitian **Rasio Neutrofil Limfosit dan Kadar Squamous Cell Carcinoma Antigen (SCCA) Serum pada Pasien Kanker Paru.**

Penyakit paru merupakan kondisi yang Bapak / Ibu / Saudara (i) sering dengar, salah satu jenisnya adalah kanker paru. Rasio neutrofil limfosit dan SCCA merupakan salah satu penanda tumor pada kanker paru. Saya akan melakukan penelitian uji diagnosis rasio neutrofil limfosit dan SCCA bertujuan untuk melihat sensitifitas dan spesifisitas penanda tumor tersebut pada pasien kanker paru. Manfaat yang dapat diambil dari aspek klinis adalah semakin awal terdeteksi kanker paru maka prognosis dan tatalaksana akan semakin baik.

Adapun penelitian ini tidak memaksa keikutsertaan Bapak / Ibu / saudara (i) dan jika Bapak / Ibu / saudara (i) bersedia menandatangani formulir kesediaan ikut serta dalam penelitian dengan sukarela. Bapak / Ibu / saudara (i) tidak perlu khawatir ketidakikutsertaan anda dalam penelitian ini tidak mengurangi pelayanan kesehatan yang akan diperoleh dari pihak rumah sakit. Prosedur yang akan kami lakukan adalah mengambil sampel darah melalui pembuluh darah di bagian lengan dengan menggunakan jarum. Sampel darah diambil sebanyak minimal 3 cc. Risiko yang dapat timbul saat pengambilan darah berupa kebiruan di daerah suntikan. Hal ini bisa terjadi dan akan perlahan-lahan menghilang. Cara penanganan jika terjadi kebiruan adalah mengompres dengan air dingin dan membalut bila terjadi perdarahan di area bekas suntikan, dapat dilakukan penekanan guna menghentikan perdarahan dan mengangkat bagian tubuh lebih tinggi dari jantung untuk mengurangi aliran darah ke daerah yang mengalami perdarahan. Penelitian ini tidak dipungut bayaran sama sekali. Sampel darah dimasukkan ke dalam tabung kecil khusus lalu dibawa ke laboratorium untuk dilakukan pemeriksaan SCCA. Bapak / Ibu / saudara (i), kami tidak memberikan kompensasi untuk pemeriksaan ini, namun Bapak / Ibu / saudara (i) dapat mengetahui hasil pemeriksaan ini yang bermanfaat untuk menilai tingkat atau stadium dari penyakit paru yang dialami sehingga bisa lebih memperhatikan dan mempertimbangkan hal-hal yang dapat memperparah kondisi ini.

Kami menjamin keamanan dan kerahasiaan semua data pada penelitian ini. Data akan disimpan dengan baik dan aman sehingga hanya bisa dilihat oleh yang berkepentingan saja. Data pribadi disamarkan pada semua catatan dan pada pelaporan baik lisan ataupun tertulis tidak akan menggunakan data pribadi. Adapun sampel darah Bapak / Ibu / Saudara (i) jika tidak dapat digunakan atau bila terdapat sampel yang tersisa, maka sampel tersebut tidak kami pergunakan untuk tujuan penelitian lain selain yang telah kami sebutkan diatas. Jika ada hal yang ingin ditanyakan mengenai penelitian ini dapat menghubungi peneliti dengan alamat dan nomor kontak di bawah ini.

Identitas Peneliti:

Nama : dr. Tuti Alawiyah

Alamat : Jl. Suka Maju II No. 3B Kel. Tamamaung, Panakkukang, Makassar.

No Hp : 081314847985

Lampiran 3. Formulir Informed Consent

FORMULIR PERSETUJUAN SETELAH PENJELASAN

Rasio Neutrofil Limfosit dan Kadar Squamous Cell Carcinoma Antigen (SCCA) Serum pada Pasien Kanker Paru.

Saya yang bertandatangan di bawah ini :

Nama :
 Umur :
 Masa Kerja :
 Satuan :
 Alamat :

setelah mendengar/membaca dan mengerti penjelasan yang diberikan mengenai tujuan, manfaat, dan apa yang akan dilakukan pada penelitian ini, menyatakan setuju untuk ikut dalam penelitian ini secara sukarela tanpa paksaan.

Saya tahu bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan, sehingga saya bisa menolak ikut atau mengundurkan diri dari penelitian ini. Saya berhak bertanya atau meminta penjelasan pada peneliti bila masih ada hal yang belum jelas atau masih ada hal yang ingin saya ketahui tentang penelitian ini.

Saya juga mengerti bahwa semua biaya yang dikeluarkan sehubungan dengan penelitian ini, akan ditanggung oleh peneliti. Saya percaya bahwa keamanan dan kerahasiaan data penelitian akan terjamin dan saya dengan ini menyetujui semua data saya yang dihasilkan pada penelitian ini untuk disajikan dalam bentuk lisan maupun tulisan.

Dengan membubuhkan tandatangan saya di bawah ini, saya menegaskan keikutsertaan saya secara sukarela dalam studi penelitian ini.

Nama	Tanda tangan	Tgl/Bln/Thn
------	--------------	-------------

Responden/Wali		
----------------------	-------	-------

Saksi		
-------------	-------	-------

(Tanda Tangan Saksi diperlukan hanya jika Partisipan tidak dapat memberikan consent/persetujuan sehingga menggunakan wali yang sah secara hukum, yaitu untuk partisipan berikut:

1. Berusia di bawah 18 tahun
2. Usia lanjut
3. Gangguan mental
4. Pasien tidak sadar
5. Dan lain-lain kondisi yang tidak memungkinkan memberikan persetujuan

Lampiran 4. Data Penelitian

No	JK	Usia	Lokasi Tumor	Hasil Histopatologi	T	N	M	Stage	N	L	NLR	SCCA
1	L	64	Kanan	Karsinoma sel squamosa	T4	N0	M0	IIIa	65,4	26,7	2,45	4,02
2	L	49	Kanan	Adenokarsinoma	T3	N1	M0	IIIa	87,1	8,5	10,25	2,47
3	P	55	Kiri	Karsinoma sel squamosa	T4	N0	M1c	IVb	76,5	12,6	6,07	6,70
4	L	66	Kanan	Karsinoma sel squamosa	T4	N2	M1a	IVa	81,4	8,6	9,47	28,82
5	L	37	Kanan	Adenokarsinoma	T4	N3	M0	IIIc	69,3	21	3,30	3,65
6	L	56	Kiri	Adenokarsinoma	T4	N1	M1c	IVb	92,5	4,5	20,56	5,57
7	P	51	Kanan	Adenokarsinoma	T3	N2	M1a	IVa	74,3	15,8	4,70	2,05
8	P	46	Kanan	Adenokarsinoma	T4	N3	M1a	IVb	67,8	20,3	3,34	3,31
9	P	71	Kanan	Adenosquamous cell carcinoma	T4	N1	M0	IIIa	53,1	38	1,40	2,74
10	P	39	Kiri	Adenokarsinoma	T1	N3	M0	IIIb	57,4	32,2	1,78	4,49
11	L	47	Kanan	Karsinoma sel squamosa	T2b	N0	M1a	IVa	70,9	12,7	5,58	3,02
12	P	59	Kanan	Karsinoma sel squamosa	T1c	N1	M1b	IVa	88	5,5	16,00	2,65
13	L	71	Kanan	Adenokarsinoma	T4	N3	M1c	IVb	84,8	9,7	8,74	4,15
14	P	51	Kanan	Adenokarsinoma	T3	N0	M1b	IVa	76,8	17,3	4,44	3,97
15	L	61	Kiri	Karsinoma sel squamosa	T4	N3	M1b	IVa	83,3	6,9	12,07	3,50
16	L	64	Kanan	Karsinoma sel squamosa	T4	N0	M0	IIIa	49,3	37,3	1,32	1,93
17	P	64	Kanan	Karsinoma sel squamosa	T3	N3	M1c	IVb	81,5	11,7	6,97	6,17
18	P	50	Kanan	Adenokarsinoma	T4	N3	M1a	IVa	78,1	10,5	7,44	1,33
19	P	56	Kiri	Karsinoma sel squamosa	T4	N0	M1c	IVb	76,1	12,7	5,99	2,90
20	L	67	Kiri	Karsinoma sel squamosa	T4	N2	M1c	IVa	79,1	12	6,59	3,13
21	L	60	Kanan	Karsinoma sel squamosa	T4	N0	M1a	IVa	97	2,4	40,42	18,16
22	L	66	Kanan	Adenokarsinoma	T4	N3	M1b	IVa	93,8	1,6	58,63	1,73
23	L	61	Kanan	Adenosquamous cell carcinoma	T4	N2	M1a	IVa	72,1	13,3	5,42	2,08
24	L	47	Kiri	Karsinoma sel squamosa	T4	M3	M1a	IVa	92,6	5,1	18,16	12,24
25	L	53	Kiri	Karsinoma sel squamosa	T2b	N3	M1b	IVa	57,4	18,7	3,07	2,76
26	P	57	Kanan	Karsinoma sel squamosa	T3	N0	M0	IIIa	84,5	7,9	10,70	3,00

27	L	68	Kanan	Karsinoma sel squamosa	T3	N3	M1c	IVb	70,6	16,2	4,36	1,08
28	L	53	Kanan	Karsinoma sel squamosa	T4	N2	M1b	IVa	82,4	13,5	6,10	1,77
29	L	48	Kanan	Karsinoma sel squamosa	T4	N2	M0	IIIb	51	28,9	1,76	1,90
30	L	58	Kanan	Adenokarsinoma	T1	N2	M1c	IVb	70	18,9	3,70	7,01
31	L	49	Kanan	Karsinoma sel squamosa	T4	N1	M1a	IVa	80,7	13	6,21	3,50
32	P	63	Kiri	Karsinoma sel squamosa	T4	N3	M1b	IVa	84,5	7,7	10,97	2,87
33	L	74	Kanan	Adenosquamous cell carcinoma	T4	N3	M0	IVa	80,9	14,3	5,66	2,20
34	L	45	Kanan	Karsinoma sel squamosa	T2	N3	M1c	IVb	91,5	3,6	25,42	2,52
35	L	69	Kiri	Adenokarsinoma	T4	N0	M1a	IVa	76,2	15,2	5,01	1,13
36	L	66	Kiri	Adenokarsinoma	T4	N2	M0	IIIb	54,6	28,4	1,92	3,33
37	L	63	Kiri	Adenokarsinoma	T3	N3	M1c	IVb	74,1	9,6	7,72	2,11
38	L	60	Kanan	Adenosquamous cell carcinoma	T4	N3	M1c	IVb	91,7	3,9	23,51	2,18
39	L	56	Kiri	Karsinoma sel squamosa	T4	N0	M0	IVa	81,6	9,9	8,24	1,58
40	L	43	Kiri	Karsinoma sel squamosa	T4	N0	M1a	IVa	70,3	15,4	4,56	3,02
41	L	69	Kanan	Adenosquamous cell carcinoma	T4	N0	M1b	IVa	83,4	9,4	8,87	3,27
42	L	72	Kanan	Karsinoma sel squamosa	T3	N2	M0	IIIb	78,6	15,4	5,10	2,47
43	L	65	Kiri	Adenokarsinoma	T4	N3	M1a	IVA	72,3	13,2	5,48	1,46
44	P	64	Kiri	Adenosquamous cell carcinoma	T3	N3	M1a	IVA	75,8	13,4	5,66	1,62
45	L	55	Kanan	Adenokarsinoma	T4	N1	M0	IIIA	57	25,5	2,24	5,15
46	L	63	Kiri	Adenokarsinoma	T3	N3	M1c	IVB	71,3	10,8	6,60	2,62
47	P	71	Kiri	Adenosquamous cell carcinoma	T4	N1	M0	IIIA	53,1	38	1,40	1,83
48	L	20	Kanan	Karsinoma sel squamosa	T4	N0	M1b	IVA	90,2	3,5	25,77	2,20
49	L	67	Kiri	Adenokarsinoma	T4	N2	M1a	IVA	50,1	38,5	1,30	3,13
50	P	71	Kanan	Adenokarsinoma	T3	N3	M1c	IVB	85,1	8,7	9,78	0,35
51	P	53	Kanan	Adenokarsinoma	T4	N2	M1c	IVb	84,1	7,7	10,92	0,84
52	P	51	Kanan	Adenokarsinoma	T3	N2	M1a	IVa	63,1	23,9	2,64	2,11
53	L	56	Kanan	Adenokarsinoma	T4	N3	M1b	IVa	65,4	15,2	4,30	1,08
54	L	64	Kiri	Karsinoma sel squamosa	T3	N2	M0	IIIb	65,6	14,6	4,49	2,76
55	L	68	Kanan	Karsinoma sel squamosa	T1	N3	M1c	IVb	43,5	15,4	2,82	3,02

56	L	69	Kiri	Karsinoma sel squamosa	T2b	N0	M1a	IVa	89,5	7,1	12,61	2,39
57	L	72	Kanan	Adenokarsinoma	T4	N2	M0	IIIb	85,9	6,7	12,82	3,27
58	P	66	Kanan	Karsinoma sel squamosa	T4	N2	M1a	IVa	68,9	22,8	3,02	12,48
59	L	63	Kanan	Karsinoma sel squamosa	T4	N2	M0	IIIb	63,9	23,1	2,77	2,96
60	P	54	Kanan	Karsinoma sel squamosa	T4	N3	M0	IVa	74,1	19,1	3,88	2,31
61	L	62	Kanan	Adenokarsinoma	T4	N3	M1a	IVa	68,3	10,6	6,44	1,42
62	L	56	Kiri	Karsinoma sel squamosa	T2b	N3	M1b	IVa	87	5,6	15,54	2,96
63	L	84	Kanan	Adenokarsinoma	T1a	N2	M1c	IVb	72,1	18,3	3,94	1,37
64	L	56	Kiri	Adenokarsinoma	T4	N3	M1c	IVb	78,5	12,9	6,09	2,92
65	L	54	Kiri	Adenokarsinoma	T4	N0	M0	IIIb	56,5	28,5	1,98	3,15
66	L	64	Kanan	Karsinoma sel squamosa	T1	N3	M1c	IVb	89,4	7,7	11,61	2,54
67	L	69	Kanan	Karsinoma sel squamosa	T4	N0	M1	IIIb	84,5	3,2	26,41	1,76
68	P	37	Kiri	Adenokarsinoma	T4	N3	M0	IIIa	80,5	5,4	14,91	2,11
69	L	49	Kiri	Adenokarsinoma	T4	N0	M0	IIIa	59,9	25,2	2,38	1,54
70	L	55	Kiri	Adenokarsinoma	T4	N3	M1a	IVa	56,7	26,1	2,17	2,29
71	P	65	Kiri	Adenokarsinoma	T3	N2	M0	IVa	61,9	22,6	2,74	2,78
72	P	76	Kanan	Karsinoma sel squamosa	T4	N0	M0	IVa	84,5	6,3	13,41	2,08
73	L	57	Kanan	Adenokarsinoma	T4	N2	M1a	IVb	69,1	18,2	3,80	2,39

Lampiran 5. Curriculum Vitae

DATA PRIBADI

Nama : dr. Tuti Alawiyah
 Tempat, tanggal lahir : Bogor, 11 November 1987
 Agama : Islam
 Pekerjaan : Mahasiswa PPDS
 Alamat Domisili : Jl. Sukamaju II No. 3B, Panakkukang

RIWAYAT PENDIDIKAN

NO	STRATA	INSTITUSI	TEMPAT	TAHUN TAMAT
1	SD	SDN 3 Bojonggede	Kab. Bogor	1999
2	SMP	PONPES Alhamidiyah	Depok, Jawa Barat	2002
3	SMA	PONPES Alhamidiyah	Depok, Jawa Barat	2005
4	Dokter	FK UIN Syarif Hidayatullah	Jakarta	2010
5	Spesialis	Prodi Ilmu Patologi Klinik FK-UNHAS	Makassar	Januari 2021 - Sekarang

RIWAYAT PEKERJAAN

NO	Jabatan	Instansi	Tempat	Periode
1	Dokter Umum	Puskesmas Manyafun	Raja Ampat, Papua Barat	2012 - 2015
2	Dokter Umum	KPRI Najwa Medika	Depok, Jawa Barat	2015 - 2021